Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

552 TRAZODONE
Hair
Hair – alopecia
(2000): Mercke Y+, Ann Clin Psychiatry 12, 35
(1988): Warnock JK+, Am J Psychiatry 145, 425
Nails
Nails – leukonychia
(1985): Longstreth GF+, JAmAcadDermatol13, 149
Other
Gynecomastia
Hypersensitivity
Myalgia/Myositis/Myopathy/Myotoxicity (1–10%)
TREPROSTINIL
Trade name: Remodulin (United)
Indications: Pulmonary arterial hypertension
Category: Platelet aggregation inhibitor; Prostaglandin
Half-life: 2–4 hours
Clinically important, potentially hazardous interactions
with: anticoagulants, antihypertensives, diuretics, vasodilators
Reactions
Skin
Diaphoresis
Edema (9%)
(2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615
Erythema
Peripheral edema
Pruritus (8%)
Rash (sic) (14%)
Other
Application-site reactions (sic) (83%)
Injection-site bleeding (33%)
Injection-site erythema
(2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615
Injection-site induration
Injection-site pain (85%)
(2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615
(2002): Simonneau G+, Am J Respir Crit Care Md 165(6), 800
(2002): Vachiery JL+, Chest 121(5), 1561
Injection-site reactions (sic) (83%)
Pain (13%)
(2002): Horn EM+, Expert Opin Investig Drugs 11(11), 1615
TRETINOIN
Synonym: All-trans-retinoic acid
Trade names: A-Acido; Aberal; Aberela; Acid A Vit; Acnavit;
Acta; Airol; Aknemycin Plus (EM Industries); Alquingel; Alten;
ATRA; Atragen; Avita; Avitcid; Avitoin; Cordes VAS; Derm A;
Dermairol; Dermojuventus; Epi-Aberel; Eudyna; Relief; Renova
(Ortho); Retin-A Micro (Ortho); Retinoic Acid; Retinova; Solage
(Galderma); SteiVAA; Stieva-A; Vesanoid (Roche); Vitamin A Acid
Indications: Acne vulgaris, skin aging, facial roughness, fine wrinkles,
hyperpigmentation [T], acute promyelocytic leukemia (APL) [O]
Category: Retinoid
Half-life: 0.5–2 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, bexarotene
Note: [T] = Topical, [O] = Oral
Reactions
Skin
Acne (1%)
(1996): Shalita A+, JAmAcadDermatol34, 482
Acute febrile neutrophilic dermatosis (Sweet’s syndrome)
(2007): Jagdeo J+, JAmAcadDermatol56(4), 690
(2007): Thompson DF+, Ann Pharmacother 41(5), 802
(2005): Shimizu D+, Intern Med 44(5), 480
(2004): Al-Saad K+, J Pediatr Hematol Oncol 26(3), 197
(2002): Astudillo L+, Ann Hematol 81(2), 111
(2001): Park CJ+, Korean J Intern Med 16(3), 218
(2000): Ueno R+, Rinsho Ketsueki 41(9), 718
(2000): van Der Vliet HJ+, Am J Hematol 63(2), 94
(1999): Levi I+, Leuk Lymphoma 34(3–4), 401
(1999): Takada S+, Int J Hematol 70(1), 26
(1998): Arun B+, Leuk Lymphoma 31(5–6), 613
(1997): Hatake K+, Int J Hematol 66(1), 13
(1996): Christ E+, Leukemia 10(4), 731
(1995): Shirono K+, Int J Hematol 62(3), 183
(1994): Cox NH+, Clin Exp Dermatol 19(1), 51
(1994): Piette WW+, JAmAcadDermatol30(2 Pt 2), 293
(1994): Tomas JF+, Leukemia 8(9), 1596
Bullous dermatitis
(1998): Webster GF, JAmAcadDermatol39, S38–44
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126–34
Burning (10–40%) [O][T]
(2001): Egan N+, Cutis 68(4 Suppl), 20
(2001): Vandana B+, AAPS PharmSciTech 2(3), Technical Note 4
(1998): Ellis CN+, Br J Dermatol 139 Suppl 52, 41
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Drug Information Handbook Fifth Ed., American
Pharmaceutical Association Hudson, OH
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
(1997): Gilchrest B, JAmAcadDermatol36, S27–36
(1996): Shalita A+, JAmAcadDermatol34, 482
(1996): Shroot B, Presented at Dermatology Update ‘95
(Montreal) (Canada)
(1995): Package Insert Hoffman-LaRoche, Inc. Nutley, NJ
(1995): Hall R, Inpharma December, 13
(1992): Olsen EA+, JAmAcadDermatol26, 215
(1991): Weinstein GD+, Arch Dermatol 127, 659
(1989): Goldfarb MT+, JAmAcadDermatol21, 645
(1989): Leyden JJ+, JAmAcadDermatol21, 638
(1988): Cohen BA+, Pediatric Dermatology 1, New York:
Churchill Livingstone, 663
Carcinoma [O]
Cellulitis (1–10%) [O]
(1997): Drug Information Handbook Fifth Ed., American
Pharmaceutical Association Hudson, OH
(1995): Package insert Hoffman-LaRoche, Inc. Nutley, NJ
(1995): Gillis JC+, Drugs 50(5), 897
Crusting
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126
Dermatitis
(1997): Gilchrest B, JAmAcadDermatol36, S27
(1992): Olsen EA+, JAmAcadDermatol26, 215
(1991): Weinstein GD+, Arch Dermatol 127, 659
(1989): Goldfarb MT+, JAmAcadDermatol21, 645
(1989): Leyden JJ+, JAmAcadDermatol21, 638
Desquamation (14%)
Diaphoresis (20%)
Edema (29%)
(1998): Webster GF, JAmAcadDermatol39, S38
(1997): Drug Information Handbook Fifth Ed. American
Pharmaceutical Association, Hudson, OH (29%) ([O])
(1997): Cunliffe WJ+, JAmAcadDermatol36, S126